Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity

Figures & data

Table 1 Demographic characteristics of the included patients and PCA at treatment

	Number of patients	Number of eyes	GA, weeks (mean ± SD)	BW, grams (mean ± SD)	PCA at treatment, weeks (mean ± SD)
Group 1 IVR	8	16	28.1±3.8	1,329±328	36.6±1.9
Group 2 IVR + laser	21	41	29.9±2.0	1,214±229	38.2±3.0
Total	29	57	29.4±2.2	1,272±255	37.7±2.6

Abbreviations: PCA, postconceptional age; GA, gestational age; BW, birth weight; SD, standard deviation; IVR, intravitreal ranibizumab.

Figure 1 Image before IVR monotherapy (A); 6 days after IVR monotherapy (B); and after 6 months of IVR monotherapy (C).

Abbreviation: IVR, intravitreal ranibizumab.

Table 2 Results of treatment according to groups

	Number of included eyes	Favorable outcomes, n eyes (%)	Unfavorable outcomes, n eyes (%)
Group 1 IVR	16	14 (87.5%)	2 (12.5%)
Group 2 IVR + laser
Group 2 (A + B)	41	29 (70.7%)	12 (29.3%)
Group 2A: initial IVR	13	13 (100%)	0 (0%)
Group 2B: initial laser	28	16 (57.1%)	12 (42.8%)
Total	57	43 (75.4%)	14 (24.6%)

Abbreviation: IVR, intravitreal ranibizumab.